A phase IIa/b multicentre study (https://clinicaltrials.gov/ct2/show/NCT05516498) has commenced comparing zibotentan and dapagliflozin in combination with dapagliflozin monotherapy versus placebo in patients with cirrhosis and features of PH to assess the effects of endothelin receptor/SGLT2 combinatorial drug strategy [71]. The gene discussed is SLC5A2; the disease is Cirrhosis.